Future financial support for family caregivers on the table for 2023 with expiration of Utah s Medicaid HCBS waiver amendment - State of Reform stateofreform.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stateofreform.com Daily Mail and Mail on Sunday newspapers.
Share this article
LA JOLLA, Calif., March 9, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the Company or Regulus ), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. Regulus finished the year on a high note , stated Jay Hagan, CEO of Regulus. We advanced RGLS4326 into a Phase 1b study in ADPKD patients, achieved an enrollment milestone for RG-012 with Sanofi and its Phase 2 clinical study for the treatment of patients with Alport syndrome, and completed a private financing. With the recent progress, we believe we are well positioned to advance the ADPKD program through Phase 1b while also advancing our next generation ADPKD compound toward the clinic.
Regulus Announces Addition to Board of Directors
News provided by
Share this article
LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company s board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee. We are pleased to add Dr. Huang to the Regulus board. We believe her extensive scientific background will be of benefit to helping direct the Company s drug discovery and development programs, said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.